Literature DB >> 16488330

What have we learned in dermatology from the biologic therapies?

Brian J Nickoloff, Seth R Stevens.   

Abstract

Recent advances in our basic understanding of immunology, specifically the roles of various cell types involved in immune response and the action of cytokines they produce, has radically changed our understanding of the origin of inflammatory dermatoses, and other autoimmune diseases. Broadened comprehension of the immune response on a molecular level has facilitated the development of biologic therapeutics for the treatment of psoriasis, atopic dermatosis, and other inflammatory conditions. However, despite major advances in development and use of targeted biologics for controlling autoimmune disease, effective cures for these conditions remain to be developed and genetic determinants of predisposition to such diseases remain to be identified. Here, we review the history of our understanding of inflammatory dermatoses, traditional and new treatment approaches, and future directions for research and therapy in this area.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16488330     DOI: 10.1016/j.jaad.2005.10.059

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  8 in total

1.  Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2013 MauiDerm Meeting.

Authors:  Andrew Blauvelt; Marc Brown; Kenneth B Gordon; Arthur Kavanaugh; Craig T Leonardi; Eggert Stockfleth; Bruce Strober; Neil A Swanson; George Martin
Journal:  J Clin Aesthet Dermatol       Date:  2013-09

2.  Activation of keratinocyte protein kinase C zeta in psoriasis plaques.

Authors:  Yuming Zhao; Rita Fishelevich; John P Petrali; Lida Zheng; Malinina Alla Anatolievna; April Deng; Richard L Eckert; Anthony A Gaspari
Journal:  J Invest Dermatol       Date:  2008-04-03       Impact factor: 8.551

3.  Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes.

Authors:  Lisa C Zaba; Mayte Suárez-Fariñas; Judilyn Fuentes-Duculan; Kristine E Nograles; Emma Guttman-Yassky; Irma Cardinale; Michelle A Lowes; James G Krueger
Journal:  J Allergy Clin Immunol       Date:  2009-11       Impact factor: 10.793

4.  Tumor necrosis factor receptor 1/c-Jun-NH2-kinase signaling promotes human neoplasia.

Authors:  Jennifer Y Zhang; Amy E Adams; Todd W Ridky; Shiying Tao; Paul A Khavari
Journal:  Cancer Res       Date:  2007-04-15       Impact factor: 12.701

Review 5.  Off-label biologic regimens in psoriasis: a systematic review of efficacy and safety of dose escalation, reduction, and interrupted biologic therapy.

Authors:  Elizabeth A Brezinski; April W Armstrong
Journal:  PLoS One       Date:  2012-04-11       Impact factor: 3.240

6.  Economic Factors as Major Determinants of Ustekinumab Drug Survival of Patients with Chronic Plaque Psoriasis in Korea.

Authors:  Chong Won Choi; Seungkeol Yang; Gwanghyun Jo; Bo Ri Kim; Sang Woong Youn
Journal:  Ann Dermatol       Date:  2018-10-26       Impact factor: 1.444

Review 7.  The role of dendritic cells in the immunopathogenesis of psoriasis.

Authors:  Sunit P Jariwala
Journal:  Arch Dermatol Res       Date:  2007-08-07       Impact factor: 3.017

8.  Economic Burden Can Be the Major Determining Factor Resulting in Short-Term Intermittent and Repetitive Ustekinumab Treatment for Moderate-to-Severe Psoriasis.

Authors:  Chong Won Choi; Ji Young Choi; Bo Ri Kim; Sang Woong Youn
Journal:  Ann Dermatol       Date:  2018-02-21       Impact factor: 1.444

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.